Pasar al contenido principal

CARACTERIZACION DE LA PIROPTOSIS INDUCIDA POR GASDERMINAS EN EL DESARROLLO DE ENFERMEDADES METABOLICAS

PID2020-116709RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIÓN PARA LA FORMACIÓN E INVESTIGACIÓN SANITARIAS DE LA REGIÓN DE MURCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Increased expression of the ATP-gated P2X7 receptor reduces responsiveness to anti-convulsants during status epilepticus in mice

  • Beamer, Edward
  • Morgan, James
  • Alves, Mariana
  • Menendez Mendez, Aida
  • Morris, Gareth
  • Zimmer, Bela
  • Conte, Giorgia
  • De Diego García, Laura
  • Alarcon Vila, Cristina
  • Yiu Ng, Nico Ka
  • Madden, Stephen
  • Calzaferri, Francesco
  • de los Rios, Cristobal
  • Garcia, Antonio G
  • Hamacher, Michael
  • Dinkel, Klaus
  • Pelegrin, Pablo
  • Henshall, DC
  • Nicke, Annette
  • Engel, Tobias
Background and Purpose: Refractory status epilepticus is a clinical emergency associated with high mortality and morbidity. Increasing evidence suggests neuroinflammation contributes to the development of drug-refractoriness during status epilepticus. Here, we have determined the contribution of the ATP-gated P2X7 receptor, previously linked to inflammation and increased hyperexcitability, to drug refractory status epilepticus and its therapeutic potential. Experimental Approach: Status epilepticus was induced via a unilateral microinjection of kainic acid into the amygdala in adult mice. Severity of status epilepticus was compared in animals with overexpressing or knock-out of the P2X7 receptor, after inflammatory priming by pre-injection of bacterial lipopolysaccharide (LPS) and in mice treated with P2X7 receptor-targeting and anti-inflammatory drugs. Key Results: Mice overexpressing P2X7 receptors were unresponsive to several anticonvulsants (lorazepam, midazolam, phenytoin and carbamazepine) during status epilepticus. P2X7 receptor expression increased in microglia during status epilepticus, at times when responses to anticonvulsants were reduced. Overexpression of P2X7 receptors induced a pro-inflammatory phenotype in microglia during status epilepticus and the anti-inflammatory drug minocycline restored normal responses to anticonvulsants in mice overexpressing P2X7 receptors. Pretreatment of wild-type mice with LPS increased P2X7 receptor levels in the brain and reduced responsiveness to anticonvulsants during status epilepticus, which was overcome by either genetic deletion of P2X7 receptors or treatment with the P2X7 receptor antagonists, AFC-5128 or ITH15004. Conclusion and Implications: Our results demonstrate that P2X7 receptor-induced pro-inflammatory effects contribute to resistance to pharmacotherapy during status epilepticus. Therapies targeting P2X7 receptors could be novel adjunctive treatments for drug-refractory status epilepticus.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Novel insights into the clinical features, genetic spectrum and clonal evolution of patients carrying NLRP3 mosaicism

  • Bonet, Núria
  • Pesqué, David
  • Giménez Arnau, Anna Maria
  • Laayouni, Hafid, 1968-
  • Fornas Carreño, Oscar
  • Aróstegui Gorospe, Juan Ignacio
NLRP3 mosaicism is a well-established mechanism causing the monogenic autoinflammatory disease named cryopyrin-associated periodic syndromes (CAPS). The number of reported patients with NLRP3 mosaicism is small, and the knowledge about the long-term disease behavior is limited. Herein we assembled the largest cohort of individuals with NLRP3 mosaicism reported to date to obtain additional evidence that strengthens the understanding of this disease. The novel genetic data were obtained by using Sanger and next-generation sequencing methods, whereas in vitro analyses determined the functional consequences of detected variants. A total of seventeen individuals with NLRP3 mosaicism were enrolled, with 16/17 experiencing different CAPS phenotypes. An overrepresentation of late-onset forms was detected (37.5%). Overall, clinical manifestations, analytical results, and outcomes of treatments were markedly similar to those detected in patients with germline variants. A large mutational diversity was identified, with 16 different variants among 17 individuals. Two main patterns of mosaicism (extended vs. myeloid-restricted) were detected, with the last one overrepresented in the late-onset group. The evaluation of mosaicism over time identified three different patterns, being the group with stable mosaicism the largest one. Collected evidence supports the marked similarities among patients carrying somatic or germline NLRP3 variants. The overrepresentation of NLRP3 mosaicism in late-onset forms should be considered in patients with inflammatory manifestations starting in adulthood. Analysis of mosaicism at the biological level confirms the two known patterns of corporal distribution and reveals that mosaicism remains stable over time in most patients, but it may also vary during the course of the disease., This work has been partially funded by: • PID2021-125106OB-C31 (JIA), PID2020-116709RB-I00 (PP), CNS2022-135101 (PP), PID2023-147531OB-I00 (PP), PID2021-125106OB-C32 (FC), RED2022-134511-T (PP, JIA) and PID2021-125106OB-C33 (OF) grants from the Ministerio de Ciencia e Innovación (MCIN) | Agencia Estatal de Investigación (AEI) | https://doi.org/10.13039/501100011033 | Fondo Europeo de Desarrollo Regional (FEDER), UE | European Union «Next Generation EU/PRTR». • AC21_2/00042 (JIA) and IFI22/00031 (JG-V) grants from the Instituto de Salud Carlos III co-funded by Unión Europea Next Generation EU | Mecanismo para la Recuperación y la Resiliencia (MRR) | Plan de Recuperación, Transformación y Resiliencia (PRTR). • 2021SGR01093 | Agència de Gestió d’Ajuts Universitaris i de Recerca | Generalitat de Catalunya (FC). • 21897/PI/22 (PP) and 21214/FPI/19 (LH-N) | Fundación Séneca, Región de Murcia, Spain.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

  • Hurtado Navarro, Laura
  • Bellosillo Paricio, Beatriz
  • García-Ávila, Sara
  • Ferrer-Marín, Francisca
Chronic myelomonocytic leukemia (CMML) is frequently associated with mutations in the rat sarcoma gene (RAS), leading to worse prognosis. RAS mutations result in active RAS-GTP proteins, favoring myeloid cell proliferation and survival and inducing the NLRP3 inflammasome together with the apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), which promote caspase-1 activation and interleukin (IL)-1β release. Here, we report, in a cohort of CMML patients with mutations in KRAS, a constitutive activation of the NLRP3 inflammasome in monocytes, evidenced by ASC oligomerization and IL-1β release, as well as a specific inflammatory cytokine signature. Treatment of a CMML patient with a KRASG12D mutation using the IL-1 receptor blocker anakinra inhibits NLRP3 inflammasome activation, reduces monocyte count, and improves the patient's clinical status, enabling a stem cell transplant. This reveals a basal inflammasome activation in RAS-mutated CMML patients and suggests potential therapeutic applications of NLRP3 and IL-1 blockers., This work was supported by grants to P.P. from MCIN/AEI/10.13039/501100011033 (grant PID2020-116709RB-I00), Fundación Séneca (grants 20859/PI/18, 21897/PI/22, and 21081/PDC/19), the Instituto de Salud Carlos III (grants DTS21/00080 and AC22/00009), the EU Horizon 2020 project PlasticHeal (grant 965196), and grants from the Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional (FEDER) to F.F.-M. (PI21/00347). L.H.-N. was supported by Fellowship 21214/FPI/19 (Fundación Séneca, Región de Murcia, Spain). E.J.C.-Z. is supported by the Training of University Teachers Program (FPU18/03189). M.L.M. is supported by Next Generation EU grant (PMP21/00052). This study was approved by the Clinical Research Ethics Committee of the Hospital Universitario Morales-Meseguer (reference no. 07/19). All patients and donors provided written informed consent in accordance with the Declaration of Helsinki.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pathogenic NLRP3 mutants form constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1β production

  • Molina-López, Cristina
  • Hurtado-Navarro, Laura
  • García Izquierdo, Carlos
  • Angosto-Bazarra, Diego
  • Vallejo, Fernando
  • Tapia-Abellán, Ana
  • Marques-Soares, Joana R.
  • Vargas, Carmen
  • Bujan-Rivas, Segundo
  • Tomás Barberán, Francisco
  • Arostegui, Juan Ignacio
  • Pelegrin, Pablo
Cryopyrin-associated periodic syndrome (CAPS) is an autoinflammatory condition resulting from monoallelic NLRP3 variants that facilitate IL-1β production. Although these are gain-of-function variants characterized by hypersensitivity to cell priming, patients with CAPS and animal models of the disease may present inflammatory flares without identifiable external triggers. Here we find that CAPS-associated NLRP3 variants are forming constitutively active inflammasome, which induce increased basal cleavage of gasdermin D, IL-18 release and pyroptosis, with a concurrent basal pro-inflammatory gene expression signature, including the induction of nuclear receptors 4 A. The constitutively active NLRP3-inflammasome of CAPS is responsive to the selective NLRP3 inhibitor MCC950 and its activation is regulated by deubiquitination. Despite their preactivated state, the CAPS inflammasomes are responsive to activation of the NF-κB pathway. NLRP3-inflammasomes with CAPS-associated variants affect the immunometabolism of the myeloid compartment, leading to disruptions in lipids and amino acid pathways and impaired glycolysis, limiting IL-1β production. In summary, NLRP3 variants causing CAPS form a constitutively active inflammasome inducing pyroptosis and IL-18 release without cell priming, which enables the host's innate defence against pathogens while also limiting IL-1β-dependent inflammatory episodes through immunometabolism modulation, This work was supported by grants from MCIN/AEI/10.13039/501100011033 (grants PID2020-116709RB-I00, BG20/00060, CNS2022-135101 and RED2022-134511-T to PP), FEDER/Ministerio de Ciencia, Innovación y Universidades – Agencia Estatal de Investigación (grant SAF2017‐88276‐R to PP), Fundación Séneca (grants 20859/PI/18 and 21897/PI/22 to PP), the Instituto Salud Carlos III (grants DTS21/00080 and AC22/00009 to PP), the EU Horizon 2020 project PlasticHeal (grant 965196 to PP), the Spanish Ministry of Science, Innovation and Universities co-funded by the European Regional Development Fund / Agencia Estatal de Investigación (grant RTI2018-096824-B-C21 to JIA) and the Spanish Ministry of Science and Innovation / Agencia Estatal de Investigación (grant PID2021-125106OB-C31 to JIA). L.H-N. was supported by the fellowship 21214/FPI/19 (Fundación Séneca, Región de Murcia, Spain) and CM-L by was funded by the fellowship PRE2018-086824 (Ministerio economía y competitividad), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

4-octyl itaconate reduces human NLRP3 inflammasome constitutive activation with the cryopyrin-associated periodic syndrome p.R262W, p.D305N and p.T350M variants

  • Molina-López, Cristina
  • Hurtado-Navarro, Laura
  • O'Neill, Luke A. J.
  • Pelegrín, Pablo
Cryopyrin-associated periodic syndrome (CAPS) is a condition characterized by dominant genetic variants in the NLRP3 gene, which lead to the formation of constitutively active inflammasomes. These inflammasomes play a crucial role in CAPS patients' inflammatory episodes, these being primarily driven by the production of interleukin (IL)-1b. Although treatment with IL-1 blockers is effective for CAPS, some patients develop refractory responses and adverse reactions to these therapies. Consequently, there is a need for novel treatments for CAPS patients. Promising candidates are the derivatives of itaconate, which have been shown to impair NLRP3 inflammasome activation and IL-1β release in blood mononuclear cells from CAPS patients. In this study, we provide insight into the inhibitory mechanisms by which the itaconate derivative 4-octyl itaconate (4-OI) acts on NLRP3 that has different gain-of-function mutations (p.R262W, p.D305N and p.T350M) associated with CAPS. Notably, 4-OI effectively blocks the basal auto-activation of the inflammasome formed by NLRP3 p.R262W, p.D305N and p.T350M variants, which in turn reduces caspase-1 activation, gasdermin D processing, and IL-18 release. Furthermore, after lipopolysaccharide priming of macrophages, 4-OI also decreases IL-1β gene expression and release. Overall, 4-OI impairs CAPS-associated inflammasome function at multiple levels, meaning that therapeutic agents based on itaconate could be a promising therapeutic approach to managing inflammatory episodes in CAPS patients carrying p.R262W, p.D305N or p.T350M variants., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by grants from MCIN/AEI/https://doi.org/10.13039/501100011033(grants PID2020-116709RB-I00, CNS2022-135105 and RED2022-134511-T to PP), Fundación Séneca (grant 21897/PI/22 to PP), the Instituto Salud Carlos III (grant AC22/00009 to PP). L.H-N. was supported by the fellowship 21214/FPI/19 (Fundación Séneca, Región de Murcia, Spain) and CM-L by was funded by the fellowship PRE2018-086824 (Ministerio de Economía y Competitividad)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

  • Hurtado Navarro, Laura
  • Bellosillo Paricio, Beatriz
  • García-Ávila, Sara
  • Ferrer-Marín, Francisca
Chronic myelomonocytic leukemia (CMML) is frequently associated with mutations in the rat sarcoma gene (RAS), leading to worse prognosis. RAS mutations result in active RAS-GTP proteins, favoring myeloid cell proliferation and survival and inducing the NLRP3 inflammasome together with the apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), which promote caspase-1 activation and interleukin (IL)-1β release. Here, we report, in a cohort of CMML patients with mutations in KRAS, a constitutive activation of the NLRP3 inflammasome in monocytes, evidenced by ASC oligomerization and IL-1β release, as well as a specific inflammatory cytokine signature. Treatment of a CMML patient with a KRASG12D mutation using the IL-1 receptor blocker anakinra inhibits NLRP3 inflammasome activation, reduces monocyte count, and improves the patient's clinical status, enabling a stem cell transplant. This reveals a basal inflammasome activation in RAS-mutated CMML patients and suggests potential therapeutic applications of NLRP3 and IL-1 blockers., This work was supported by grants to P.P. from MCIN/AEI/10.13039/501100011033 (grant PID2020-116709RB-I00), Fundación Séneca (grants 20859/PI/18, 21897/PI/22, and 21081/PDC/19), the Instituto de Salud Carlos III (grants DTS21/00080 and AC22/00009), the EU Horizon 2020 project PlasticHeal (grant 965196), and grants from the Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional (FEDER) to F.F.-M. (PI21/00347). L.H.-N. was supported by Fellowship 21214/FPI/19 (Fundación Séneca, Región de Murcia, Spain). E.J.C.-Z. is supported by the Training of University Teachers Program (FPU18/03189). M.L.M. is supported by Next Generation EU grant (PMP21/00052). This study was approved by the Clinical Research Ethics Committee of the Hospital Universitario Morales-Meseguer (reference no. 07/19). All patients and donors provided written informed consent in accordance with the Declaration of Helsinki.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Novel insights into the clinical features, genetic spectrum and clonal evolution of patients carrying NLRP3 mosaicism

  • Bonet, Núria
  • Pesqué, David
  • Giménez Arnau, Anna Maria
  • Laayouni, Hafid, 1968-
  • Fornas Carreño, Oscar
  • Aróstegui Gorospe, Juan Ignacio
NLRP3 mosaicism is a well-established mechanism causing the monogenic autoinflammatory disease named cryopyrin-associated periodic syndromes (CAPS). The number of reported patients with NLRP3 mosaicism is small, and the knowledge about the long-term disease behavior is limited. Herein we assembled the largest cohort of individuals with NLRP3 mosaicism reported to date to obtain additional evidence that strengthens the understanding of this disease. The novel genetic data were obtained by using Sanger and next-generation sequencing methods, whereas in vitro analyses determined the functional consequences of detected variants. A total of seventeen individuals with NLRP3 mosaicism were enrolled, with 16/17 experiencing different CAPS phenotypes. An overrepresentation of late-onset forms was detected (37.5%). Overall, clinical manifestations, analytical results, and outcomes of treatments were markedly similar to those detected in patients with germline variants. A large mutational diversity was identified, with 16 different variants among 17 individuals. Two main patterns of mosaicism (extended vs. myeloid-restricted) were detected, with the last one overrepresented in the late-onset group. The evaluation of mosaicism over time identified three different patterns, being the group with stable mosaicism the largest one. Collected evidence supports the marked similarities among patients carrying somatic or germline NLRP3 variants. The overrepresentation of NLRP3 mosaicism in late-onset forms should be considered in patients with inflammatory manifestations starting in adulthood. Analysis of mosaicism at the biological level confirms the two known patterns of corporal distribution and reveals that mosaicism remains stable over time in most patients, but it may also vary during the course of the disease., This work has been partially funded by: • PID2021-125106OB-C31 (JIA), PID2020-116709RB-I00 (PP), CNS2022-135101 (PP), PID2023-147531OB-I00 (PP), PID2021-125106OB-C32 (FC), RED2022-134511-T (PP, JIA) and PID2021-125106OB-C33 (OF) grants from the Ministerio de Ciencia e Innovación (MCIN) | Agencia Estatal de Investigación (AEI) | https://doi.org/10.13039/501100011033 | Fondo Europeo de Desarrollo Regional (FEDER), UE | European Union «Next Generation EU/PRTR». • AC21_2/00042 (JIA) and IFI22/00031 (JG-V) grants from the Instituto de Salud Carlos III co-funded by Unión Europea Next Generation EU | Mecanismo para la Recuperación y la Resiliencia (MRR) | Plan de Recuperación, Transformación y Resiliencia (PRTR). • 2021SGR01093 | Agència de Gestió d’Ajuts Universitaris i de Recerca | Generalitat de Catalunya (FC). • 21897/PI/22 (PP) and 21214/FPI/19 (LH-N) | Fundación Séneca, Región de Murcia, Spain.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure

  • Malhotra, Sunny|||0000-0003-1112-7739
  • Hurtado-Navarro, Laura|||0000-0002-9544-6042
  • Pappolla, Agustin|||0000-0001-6364-9497
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Río, Jordi|||0000-0003-4546-7627
  • Montalban, Xavier|||0000-0002-0098-9918
  • Pelegrín, Pablo|||0000-0002-9688-1804
  • Comabella López, Manuel|||0000-0002-2373-6657
Inflammasomes are involved in the pathogenesis of different neuroimmune and neurodegenerative diseases, including multiple sclerosis (MS). In a previous study by our group, the nucleotide-binding oligomerization domain, leucine-rich repeat receptor and pyrin-domain-containing 3 (NLRP3) inflammasome was reported to be associated with the response to interferon-beta in MS. Based on recent data showing the potential for the oral therapy fingolimod to inhibit NLRP3 inflammasome activation, here we investigated whether fingolimod could also be implicated in the response to this therapy in patients with MS. NLRP3 gene expression levels were measured by real-time PCR in peripheral blood mononuclear cells at baseline and after 3, 6, and 12 months in a cohort of patients with MS treated with fingolimod (N = 23), dimethyl fumarate (N = 21), and teriflunomide (N = 21) and classified into responders and nonresponders to the treatment according to clinical and radiologic criteria. In a subgroup of fingolimod responders and nonresponders, the percentage of monocytes with an oligomer of ASC was determined by flow cytometry, and the levels of interleukin (IL)-1β, IL-18, IL-6, tumor necrosis factor (TNF)α, and galectin-3 were quantified by ELISA. NLPR3 expression levels were significantly increased in fingolimod nonresponders after 3 (p = 0.03) and 6 months (p = 0.008) of treatment compared with the baseline but remained similar in responders at all time points. These changes were not observed in nonresponders to the other oral therapies tested. The formation of an oligomer of ASC in monocytes after lipopolysaccharide and adenosine 5'-triphosphate stimulation was significantly decreased in responders (p = 0.006) but increased in nonresponders (p = 0.0003) after 6 months of fingolimod treatment compared with the baseline. Proinflammatory cytokine release from stimulated peripheral blood mononuclear cells was comparable between responders and nonresponders, but galectin-3 levels on cell supernatants, as a marker of cell damage, were significantly increased in fingolimod nonresponders (p = 0.02). The differential effect of fingolimod on the formation of an inflammasome-triggered ASC oligomer in monocytes between responders and nonresponders could be used as a response biomarker after 6 months of fingolimod treatment and suggests that fingolimod may exert their beneficial effects by reducing inflammasome signaling in a subset of patients with MS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

  • Hurtado-Navarro, Laura|||0000-0002-9544-6042
  • Cuenca-Zamora, Ernesto José
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Such, Esperanza|||0000-0001-6892-403X
  • Soler-Espejo, Eva
  • Martínez-Banaclocha, Helios
  • Hernández Bermúdez, J.
  • Marco-Ayala, Javier
  • Martínez-Alarcón, Laura
  • Linares-Latorre, Lola
  • Garcia-Avila, Sara|||0000-0002-9293-2029
  • Amat, Paula
  • González, Teresa
  • Arnan, Montserrat
  • Pomares-Marín, Helena
  • Carreño-Tarragona, Gonzalo|||0000-0002-9570-5542
  • Chen-Liang, Tzu Hua
  • Herranz, María T.
  • García-Palenciano, Carlos
  • Morales, María Luz
  • Jerez, Andrés|||0000-0002-2079-6638
  • Lozano, María L.
  • Teruel-Montoya, Raúl
  • Pelegrín, Pablo|||0000-0002-9688-1804
  • Ferrer-Marín, Francisca|||0000-0002-9520-3243
Chronic myelomonocytic leukemia (CMML) is frequently associated with mutations in the rat sarcoma gene (RAS), leading to worse prognosis. RAS mutations result in active RAS-GTP proteins, favoring myeloid cell proliferation and survival and inducing the NLRP3 inflammasome together with the apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), which promote caspase-1 activation and interleukin (IL)-1β release. Here, we report, in a cohort of CMML patients with mutations in KRAS, a constitutive activation of the NLRP3 inflammasome in monocytes, evidenced by ASC oligomerization and IL-1β release, as well as a specific inflammatory cytokine signature. Treatment of a CMML patient with a KRAS mutation using the IL-1 receptor blocker anakinra inhibits NLRP3 inflammasome activation, reduces monocyte count, and improves the patient's clinical status, enabling a stem cell transplant. This reveals a basal inflammasome activation in RAS-mutated CMML patients and suggests potential therapeutic applications of NLRP3 and IL-1 blockers.